Gene expression platform could revolutionize kidney transplant rejection diagnosis

NCT ID NCT07700563

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study developed and tested HistoMX, an automated platform that analyzes gene activity in kidney transplant biopsy samples. Researchers used over 2,400 archived biopsies from adult kidney transplant recipients to see if the platform could accurately identify different types of transplant injury, such as rejection or viral infection. The goal is to provide doctors with a standardized molecular report alongside traditional microscope analysis, potentially leading to more precise and consistent diagnoses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this platform could provide faster, more standardized molecular insights to help doctors diagnose kidney transplant complications more accurately.
What could go wrong
This is an observational study using archived samples, not a clinical trial testing a treatment. The platform may not improve patient outcomes or be adopted in routine practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.